Zensun Obtained Initial Results of Australian Clinical Study
2008-05-07
In 2006, Zensun initiated Phase IIa clinical study of its heart failure drug—rhNRG-1. After one and half years’ research, Zensun obtained exciting results.
The research involved three different dosages groups. It showed that the systolic function of patients with medium and high dosages improved significantly, comparing to the patients with the low dosage. This result is also consistent with the results achieved from Chinese Phase II clinical trial.
Now, Zensun are going to put more investment to facilitate the process of clinical trials.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to
